The analogues of this hormone, the glucagon-like peptide-1 receptor agonists (GLP-1RAs), are widely used in the treatment of T2DM and obesity, and their beneficial role in cardiovascular effects has now been established [6]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.